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Background: Cancer cell adopts peculiar metabolic strategies aimed to sustain the continuous proliferation in an
environment characterized by relevant fluctuations in oxygen and nutrient levels. Monocarboxylate transporters
MCT1 and MCT4 can drive such adaptation permitting the transport across plasma membrane of different
monocarboxylic acids involved in energy metabolism.
Methods: Role of MCTs in tumor-stroma metabolic relationship was investigated in vitro and in vivo using transformed
prostate epithelial cells, carcinoma cell lines and normal fibroblasts. Moreover prostate tissues from carcinoma and benign
hypertrophy cases were analyzed for individuating clinical-pathological implications of MCT1 and MCT4 expression.
Results: Transformed prostate epithelial (TPE) and prostate cancer (PCa) cells express both MCT1 and MCT4 and
demonstrated variable dependence on aerobic glycolysis for maintaining their proliferative rate. In glucose-restriction the
presence of L-lactate determined, after 24 h of treatment, in PCa cells the up-regulation of MCT1 and of cytochrome c
oxidase subunit I (COX1), and reduced the activation of AMP-activated protein kinase respect to untreated cells. The
blockade of MCT1 function, performed by si RNA silencing, determined an appreciable antiproliferative effect
when L-lactate was utilized as energetic fuel. Accordingly L-lactate released by high glycolytic human diploid fibroblasts
WI-38 sustained survival and growth of TPE and PCa cells in low glucose culture medium. In parallel, the treatment with
conditioned medium from PCa cells was sufficient to induce glycolytic metabolism in WI-38 cells, with upregulation of
HIF-1a and MCT4. Co-injection of PCa cells with high glycolytic WI-38 fibroblasts determined an impressive increase in
tumor growth rate in a xenograft model that was abrogated by MCT1 silencing in PCa cells. The possible interplay based
on L-lactate shuttle between tumor and stroma was confirmed also in human PCa tissue where we observed a positive
correlation between stromal MCT4 and tumor MCT1 expression.
Conclusions: Our data demonstrated that PCa progression may benefit of MCT1 expression in tumor cells and of MCT4
in tumor-associated stromal cells. Therefore, MCTs may result promising therapeutic targets in different phases of
neoplastic transformation according to a strategy aimed to contrast the energy metabolic adaptation of PCa
cells to stressful environments.
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Tumors have long been known to exhibit altered meta-
bolic profiles and increased energy requirements. In fact,
the high rate in cell proliferation associated with cancer
growth requires a continuous production of ATP and
cofactors, consuming glucose in excess. The exemplifica-
tive manifestation of such metabolic reprogramming is
the formation of lactic acid even in presence of oxygen,
a phenomenon referred as “aerobic glycolysis” or the
“Warburg effect” [1]. Glycolysis has been also observed
in cancer cells without defects in oxidative metabolism,
suggesting that it may provide effective advantages for
proliferating cells in both bioenergetics and biosynthesis
[2]. Growth factors, hypoxia and oncogenes stimulate
glycolysis and L-lactate production and are sufficient to
induce the Warburg effect in either non-transformed
cells or cancer cells [3]. In addition, cancer cell metabol-
ism demonstrates a high adaptability to changing envir-
onmental conditions, permitting the continuous cancer
growth in fluctuating oxygen tension and glucose con-
centration. These metabolic changes are thought to be
important hallmarks of cancer, and when occurring early
during neoplastic transformation, may provide useful
biomarkers and targets for intervention [4].
Monocarboxylate transporters (MCTs) are critical for
supporting the radical alterations seen in cancer cell me-
tabolism. MCT1 and MCT4, the best characterized mem-
bers of MCT family, are proton-linked isoforms, which
mediate in humans the transport of a range of monocar-
boxylic acids, including L-lactate, pyruvate, butyrate and
ketones, across the plasma membrane of several cell types
[5]. The differences in histologic distribution and kinetic
activities are at the basis of their specific physiologic roles.
This aspect is well represented in skeletal muscles, where
L-lactate is exported prevalently by MCT4-expressing
glycolytic fibers and it is imported and utilized by MCT1-
expressing oxidative muscle fibers [6].
MCT1 was reported to have an ubiquitous tissue dis-
tribution, and its expression is stimulated in response to
increased metabolic request or to the presence of sub-
strates [7,8]. MCT4 is expressed prevalently in those
glycolytic cells that export large amounts of lactic acid
and it is transcriptionally upregulated by hypoxia-induced
transcription factor, HIF-1. However, recent studies on the
role of L-lactate in normal metabolism have elucidated
that hypoxia is not a necessary requirement for glycolysis
and MCT4 expression. In fact, independently from hyp-
oxia, within tissues such as brain and ovary, some cells be-
come active L-lactate producers, while other cells utilize
L-lactate as mobile fuel for aerobic metabolism [9,10]. Ac-
cumulation of L-lactate has been frequently associated
also with cancer progression and it was correlated to in-
creased metastasis and poor disease-free and overall sur-
vival [11]. In parallel, upregulation of MCT1 and MCT4has been reported in several cancers, including colon,
breast and lung cancer [12], and it was associated with the
possibility to exchange L-lactate between different cancer
cells or between cancer and stromal associated cells, a
mechanism called “reverse Warburg effect” [13,14].
Prostate cancer (PCa) is usually a slow-growing malig-
nancy: hence the problem emerges of determining which
tumors demonstrate an advantage in energy metabolism.
This fact may have important consequences for thera-
peutic management of PCa, preventing unnecessary treat-
ment in patients for whom the disease is not life
threatening. Neoplastic transformation in prostate cells
coincides with restoration of full functionality in Krebs
cycle, and consequent increased generation of ATP from
glucose oxidation and low citrate levels compared to nor-
mal prostate [15]. Moreover, PCa is characterized by high
levels of L-lactate [16] and this has been linked to the
presence of hypoxic regions [17]. The hypoxia can induce
a selective pressure toward the glycolytic metabolism and
L-lactate production. However the molecular mechanisms
and the clinical impact of the metabolic changes observed
during prostate neoplastic transformation are largely
unknown.
In our study we aimed to elucidate the distribution and
the functional role, with particular regard to L-lactate
utilization, of MCT1 and MCT4 in PCa. For this reason
we investigated in vitro and in vivo the role of MCTs in
PCa cell and transformed prostate epithelial cells, and
verified the potential role of MCT1 as target in PCa ther-
apy. In addition we analyzed by immunostaining the




A total of 140 patients diagnosed for PCa (N = 80) and be-
nign prostate hypertrophy (BPH) (N = 60) and requiring
surgical treatment, were enrolled in our Urology Clinic,
Department of Medicine, the University of L’Aquila. The
research has been carried out in accordance with the Dec-
laration of Helsinki and approved by the Internal Ethical
Board of University of L’Aquila. Consent was obtained
from all patients after full explanation of the purpose of
the study. The adhesion to the study did not implicate any
modification in the routine clinical management of the pa-
tients. Inclusion criteria were: patients affected by PCa or
BPH in the age between 50 and 80 years and a body mass
index (BMI) between 25 and 30 (the most frequent range).
The diagnosis of BPH was confirmed by the histopatho-
logical analysis of the tissue obtained after transvescical
retropubic adenomectomy (TV-adenomectomy) or trans-
urethral resection of prostate (TURP). PCa was diagnosed
by routine biopsy procedure and the presence and the ex-
tension of the tumor was evaluated on the entire gland
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ing smoking habit, alcohol abuse, pharmacological therapies
as well as comorbidities was obtained for each patient en-
rolled. Systemic blood samples were drawn from overnight-
fasting patients and used to measure PSA, testosterone and
fasting insulin through routine analysis performed by our
clinical laboratory.
Animals and experimental in vivo model
Male CD1 nude mice (Charles River, Milan, Italy) were
maintained under the guidelines established by our Insti-
tution (University of L’Aquila, Medical School and Science
and Technology School Board Regulations, complying
with the Italian government regulation n.116, January 27
1992 for the use of laboratory animals) and approved by
Internal Ethical Board of University of L’Aquila. Before
any invasive manipulation, mice were anesthesized with a
mixture of ketamine (25 mg/ml)/xylazine (5 mg/ml).
Xenografts were obtained by injecting s.c. 1 × 106 tumor
cells in 500 μl of phosphate buffer saline. In groups re-
ceiving both tumor cells and fibroblasts, a ratio of 1:3
(tumor cells/ fibroblasts) was used. Metformin (Sigma,
St. Louis, MI, USA) was dissolved in cell culture medium
and was administered at a dose of 50 mg/ kg every other
day by intraperitoneal injection, with the appropriate dilu-
ent made up to a total volume of 200 μl. Tumor growth
was monitored daily by measuring the average tumor
diameter (two perpendicular axes of the tumor were
measured by a caliper). The volume of the tumor was
expressed in mm3 according to the formula: volume =
(width)2 × length/2.
Immunohistochemistry
Tissue samples were fixed in 4% formaldehyde in 0.1 M
phosphate buffer, pH 7.2 and embedded in paraffin.
Slide-mounted tissue sections (4-μm thick) were depar-
affinized in xylene and serially hydrated in 100%, 95%,
and 80% ethanol. Endogenous peroxidases were quenced
in 3% H2O2 in phosphate-buffered saline (PBS) for 1 h
and then slides were incubated with an anti-human primary
antibody (10 μg/ml) for 1 h and then with peroxidase-
conjugated secondary antibody for 30 min at room
temperature (RT). Sections were washed three times in
PBS and antibody binding was revealed using the
Sigma fast 3,30-diaminobenzidine tablet set (Sigma).
Counterstaining was performed using haematoxylin so-
lution. Anti-human MCT1 (H-70), anti-human MCT4
(H-90) and secondary antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). The
expression of MCTs was quantified using Remmele scor-
ing system [18]. The score was calculated by multiplying
the number reflecting the dominant stain intensity (0, no
detectable stain; 1, weak stain; 2, moderate stain; or 3,
strong stain) by the number reflecting the percentage ofthese positive tumor cells (0, no positive cells; 1, <10%; 2,
10-50%; 3, 51-80%; or 4, >80%). The 12-point scale was
categorized in three expression groups: 0 = no expression;
1–5 = weak expression; 6–12 = high expression.
Cell culture
LNCaP, human prostate cancer cell line isolated from
metastatic lymph node, was cultured in RPMI 1640 sup-
plemented with 10% v/v fetal bovine serum (FBS),
10 mM HEPES, 1 mM sodium pyruvate, 2 mM glutam-
ine, 100 lU/ml penicillin, and 100 μg/ml streptomycin
(Sigma). PC3, human prostate cancer cell line isolated
from bone metastasis, was cultured in Coon’s modified
Ham’s medium supplemented with 10% FBS, 2 mM glu-
tamine and penicillin-streptomycin. RWPE-1 and WPE1-
NB26, human prostate epithelial cells transformed by
human papillomavirus-18, were cultured in keratino-
cyte serum-free medium (K-SFM) with 5 ng/ml EGF
and 0.05 mg/ml bovine pituitary extract, BPE (Gibco,
Life Technologies Corporation, Grand Island, NY, USA).
Human embryonic fibroblasts WI-38 were cultured in
Dulbecco’s Modified Eagle’s Medium supplemented with
10% FBS. Cell lines were obtained from ATCC (Rockville,
MD, USA) or from ECACC (Porton Down, Salisbury,
UK). All experiments with L-lactate were performed using
its sodium salt (Sigma). For short term experiments test-
ing response to L-lactate, cells were cultured in presence
of RPMI medium without glucose (Life Technologies Cor-
poration). Conditioned medium (CM) was recovered from
cells cultured in medium without FBS for at least 24 h.
Evaluation of conditioned medium from WI-38 cells on
PCa cell proliferation in low glucose medium was per-
formed using the following scheme: CTR = 90% medium
with 0.56 g/L glucose + 10% PC3 CM; WI38 CM= 70%
medium with 0.43 g/L glucose + 30% WI-38 CM; WI38C
CM= 70% medium with 0.43 g/L glucose + 30% CM from
WI-38 conditioned with 30% PC3 CM. HIF-1α inhibitor,
3-(2-(4-Adamantan-1-yl-phenoxy)-acetylamino)-4-hydroxy-
benzoic acid methyl ester, was purchased from Calbio-
chem (Merck KGaA, Darmstadt, Germany).
Cell proliferation assay
Cells were plated at density of 104 cells/cm2 incu-
bated in 5% CO2 at 37°C and recovered after differ-
ent times of incubation. The cells were fixed for
10 min in 100% ice-cold methanol and then allowed
to air-dry. The cells were stained with 0.1% w/v
crystal violet in water for 10 min and washed with
PBS until the excess of dye was eliminated. The
stained cells were then incubated with 1% w/v SDS,
50% v/v methanol solution, and 200 μl of dissolved
dye was read at 590 nm in an ELISA reader. Optical
density at 590 nm is proportional to the number of at-
tached cells, and was used to estimate the percentage
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evaluate the presence of dead cells, cell growth was also
measured by direct cell counting assay, using a Neubauer
hemocytometer chamber and according to trypan blue
dye exclusion test. For low density growth test, cells were
plated at 10 cells/cm2, and after 2 weeks of culture, adher-
ent cells were stained with 0.1% w/v crystal violet. The
stained colonies were photomicrographed and analyzed by
number and size with the public domain software ImageJ
(Rasband, W.S., ImageJ, U. S. National Institutes of
Health, Bethesda, Maryland, USA, http://imagej.nih.
gov/ij/, 1997–2012).
Western blotting
Total cell lysates were obtained by incubating cells in a
lysis buffer containing 1% v/v Triton, 0.1% w/v SDS,
2 mM CaCl2, and 100 μg/ml phenylmethyl-sulfonyl-
fluoride. Protein content was determined using the
Protein Assay Kit 2 (Bio-Rad Laboratory, Hercules,
CA, USA). Sixty micrograms of proteins were electropho-
resed in 10% SDS–polyacrylamide gel and then electrotrans-
ferred to nitrocellulose membrane (Whatmann, Dassel,
Germany). The membrane was incubated with 1 μg/ml pri-
mary antibody and then with appropriate horseradish
peroxidase-conjugated secondary antibodies. Protein bands
were visualized using a chemiluminescent detection system
(Thermo Scientific, Rockford, IL, USA) and signals were
digitally acquired by Chemidoc XRS system (BIORAD).
Antibodies anti-β-actin, MCT1, MCT4, COX1, β-tubulin
were from Santa Cruz Biotechnology, anti HIF-1α were
from Becton Dickinson (Franklin Lakes, NJ, USA), anti-
AMPKalpha and p-AMPKalpha (Thr172) were from Cell
Signaling Technology, Inc. (Danvers, MA, USA), anti-
vimentin were from Thermo scientific (Waltham, MA,
USA), anti-αSMA were from Sigma. Densitometric
analysis of protein bands was performed using the
ImageJ software. Relative values were calculated by
comparison with experimental control, defined as 1,
and normalized by the corresponding values of loading
control (actin or β-tubulin).
Quantitative RT-PCR
Total RNA was extracted from cultured cells using Gen-
elute Mammalian Total RNA kit (Sigma) according to
the manufacturer’s protocol. RNA was quantified by
spectrophotometric analysis and 1 μg of RNA was used
to synthesize cDNA (SuperScript III Platinum Kit, Life
Technologies). Real-time PCR analysis was performed
using Stratagene MX3000P personal Q-PCR in the pres-
ence of SYBR Green. The PCR reagents were provided
in SuperScript III Platinum Kit (Life Technologies), and
the conditions were chosen according to manufacturer’s
protocol. Primers were as follows: GAPDH forward
primer: 5′-GGCCTCCAAGGAGTAAGACC-3′, reverseprimer: 5′-AGGGGTCTACATGGCAACTG-3′; MCT1
forward primer: 5′-TTCGGGTGGCTCAGCTCCGT-3′,
reverse primer: 5′-CCTCCTCCTTGGGCCCTCCA-3′;
COX1 forward primer: 5′-TCCGCTACCATAATCAT
CGCT-3′, reverse primer 5′-CCGTGGAGTGTGGC
GAGT-3′. Mean threshold cycle (Ct) values were de-
termined by Stratagene software using three distinct
amplification curves for each gene. Relative expression
of the target gene was estimated using the formula:
relative expression = 2×ΔCt, where ΔCt = Ct (target
gene) – Ct (GAPDH).
Immunofluorescence
Cells grown on coverslips (2 × 104 cells/cm2) were fixed
in 4% v/v formaldehyde in PBS for 10 min at RT and
permeabilized in PBS containing 0.1% v/v Triton X-100
for 5 min at RT. Cells were then incubated with 10 μg/ml
primary antibody, diluted in PBS containing 3% w/v bo-
vine serum albumin (BSA) for 1 h at RT. After three
washes with PBS, cells were treated with fluorescein-
labeled IgG secondary antibody (1:100 in PBS containing
3% w/v BSA) for 30 min at RT. After extensive washings,
cells were mounted with ProLong Gold antifade mounting
medium (Life Technologies Corporation) and observed by
fluorescence microscope equipped with digital camera
(AXIOPHOT, Carl Zeiss, Oberkochen, Germany).
Treatment with siRNA
In 10 cm culture dishes 1×106 cells were plated in 8 ml
antibiotic-free standard growth medium supplemented
with FBS. When cells were ∼ 60% confluent, they were
transfected for 5 h at 37°C with siRNA-MCT1 duplex or
with scramble sequence siRNA as control of gene silen-
cing (final concentration,100 nmol/L). Silencing experi-
ments were performed using four distinct 22–24 nt oligo
sequences from Riboxx life sciences (GmbH, Radebeul,
Germany) or a pool of three target-specific 19–25 nt siR-
NAs. (Santa Cruz). Transfection was performed using the
siRNA transfection reagent (Santa Cruz) or INTERFERin
kit (Polyplus transfection, New York, NY, USA) according
to the suggested protocol. Cells were cultured with siR-
NAs for 24 h before being subjected to specific treat-
ments. Data in figures are the mean of the results
obtained using different oligo sequences.
Lactate assay
Conditioned media (CM) were collected, centrifuged
for eliminating cells and were analysed through the
L-lactate Assay Kit II according to manufacturer’s in-
structions (BioVision Reasearch Products, Mountain
View, CA, USA). L-lactate concentration is determined by
an enzyme assay, based on the L-lactate oxidation by L-
lactate dehydrogenase, and the subsequent interaction
with a probe which results in the formation of a coloured
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of a 96-well plate containing 200 μl of the reaction mix
and were incubated for 30 min at RT, then optical density
was measured at 450 nm by Elisa reader within 1 h. The
concentration was calculated by applying the sample read-
ing to a standard curve. The L-lactate production rate was
calculated normalizing the concentration with total pro-
tein content for each sample (μg) and for time (min).
Statistical analyses
Descriptive data are presented as mean and standard de-
viation (SD) or median and standard error (SE) for
continuous data and percentages for categorical data.Figure 1 L-lactate export and glycolytic metabolism in PCa cell lines,
and WPE1-NB26 (WPE1). A) L-lactate export rate was calculated consider
and normalizing for total protein content (μg). B) Western blot analysis of M
from transformed epithelial cell lines, RWPE-1 and WPE1. Beta-actin detecti
of MCT4 in PC3 and LNCaP cells. In the image showing MCT4 expression i
indicate the positive staining for MCT4 mainly localized in the center of
oligomycin for different times in comparison with untreated cells. E) An
10 mM) and 3-bromo-pyruvate (3-BP, 50 μM). Percentages of viable cells re
values ± SD from at least three independent experiments.Comparisons between groups was performed by using
Student’s t-test or Pearson’s chi-square test. All tests
for statistical significance were two tailed. All analyses
were realized by using the statistical software SPSS
(Texas Instruments, Chicago, IL, USA). P < 0.05 has
been considered statistically significant.
Results
Aerobic glycolysis and L-lactate export
Both PCa cell lines, LNCaP and PC3, and TPE cell lines,
non-tumorigenic RWPE-1 and tumorigenic WPE1-NB26
(WPE1), when cultured in standard culture conditions,
enriched their culture medium with L-lactate but atLNCaP and PC3, and in transformed epithelial cell lines, RWPE-1
ing measurements at 24, 48 and 72 h in standard culture conditions
CT4 in whole cell lysates from PCa cell lines, LNCaP and PC3, and
on was utilized as loading control. C) Immunofluorescence detection
n LNCaP cells, nuclei have been visualized by DAPI staining. Arrows
cell aggregate. D) Percentages of viable cells treated with 10 μM
ti-proliferative effect of glycolysis inhibitors 2-deoxy-D-glucose (2-DG,
spect to untreated cells (100%) are reported. Data represent mean
Sanità et al. BMC Cancer 2014, 14:154 Page 6 of 14
http://www.biomedcentral.com/1471-2407/14/154different rates (Figure 1A). The lowest rate in L-lactate
export was seen in LNCaP cells and was associated with
the lowest expression of the main membrane exporter
for L-lactate, monocarboxylate transporter 4 (MCT4)
(Figure 1B). In addition, in LNCaP cells, but not in other
prostate cell lines, MCT4 expression resulted expressed
mainly in the central zone of cell aggregates (Figure 1C).
This evidence, as suggested by previous studies [19],
could be the result of the local hypoxia and, in conse-
quence, of the adaptive capacity by tumor cells. TPE and
PC3 cells demonstrated a more marked glycolytic pheno-
type respect to LNCaP cells, with PC3 cells expressing the
highest amount of MCT4 (Figure 1A and B). The dissimi-
lar dependence on aerobic glycolysis was confirmed by the
dissimilar response to oligomycin, an inhibitor of oxidative
phosphorylation. After 72 h of incubation with oligomycin
all cell lines showed an evident reduction in cell numberFigure 2 Mitogenic and survival effect of L-lactate. A) Proliferation assa
concentrations (1, 0.6, 0.2, 0 g/L) and in presence or not of 5 mM L-lactate
reference (100%). B) LNCaP cells were cultured at low density for 2 weeks
of 5 mM L-lactate (lac). At the endpoint the number of colonies and the to
LNCaP cells cultured in 0.2 g/L glucose are reported. Data represent mean
blot analysis of MCT1 in whole cell lysate from PCa cell lines, LNCaP and PC
detection was utilized as loading control. *P < 0.01 according to Student’s t testrespect to untreated cells. LNCaP cells were almost com-
pletely killed by oligomycin after 96 h of treatment, while
in the other cell lines residual viable cells were still present
(Figure 1D). The utilization of aerobic glycolysis in cell
lines was confirmed by the antiproliferative effect induced
by specific glycolysis inhibitors 2-deoxy-D-glucose and
3-bromo-pyruvate (Figure 1E).
Metabolic switch toward L-lactate import
The addition of L-lactate had inhibitory effect on cell
proliferation when prostate cells were cultured in nor-
mal culture conditions. On the contrary, in low glucose
medium, the addition of 5 mM L-lactate sustained cell
growth respect to untreated cells (Figure 2A). The mito-
genic effect of L-lactate was particularly evident when
cells were cultured at low density. In fact, long term treat-
ment of LNCaP cells with 5 mM L-lactate determined ay in prostate cell lines cultured for 48 h in decreasing glucose
(lac). Cells cultured in 0.6 g/L glucose without L-lactate were chosen as
in decreasing glucose concentrations (0.6, 0.2, 0 g/L) in presence or not
tal area covered by cells were evaluated. Representative images from
values ± SD from at least three independent experiments. C) Western
3, and from transformed epithelial cell lines, RWPE-1 and WPE1. Beta-actin
.
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colonies (Figure 2B). Both TPE and PCa cells expressed
the main importer for L-lactate, MCT1 (Figure 2C). In
addition, in LNCaP and WPE1 cells MCT1 protein ex-
pression was stimulated by L-lactate in a dose-depend
manner, and it corresponded to an increase of cytochrome
c oxidase subunit 1 expression, COX1, and in the reduc-
tion of the active form of AMP-activated protein kinase
alpha (AMPK) (Figure 3A). In presence of L-lactate we
also observed a significant upregulation in MCT1 and
COX1 mRNA (Figure 3B).
Fibroblasts are potential sources of L-lactate in tumor
microenvironment
When human fibroblasts WI-38 were cultured in presence
of PC3 conditioned medium (PC3-CM) they significantly
increased their L-lactate export respect to fibroblasts cul-
tured in serum-free medium (Figure 4A). In presence of
30% PC3-CM, fibroblasts upregulated MCT4 protein in aFigure 3 Effects of exogenous L-lactate on prostate cells. A) WPE1 and
total cell lysates were subjected to western blot analysis for MCT1, AMP ac
cytochrome c oxidase subunit 1 (COX1). Beta-actin detection was utilized a
of each protein band and were calculated as described in the Methods sec
was detected also by quantitative RT-PCR (right histogram). C) Proliferation as
prostate cells cultured for 48 h in different glucose concentrations (1, 0.6 g/L)
glucose without L-lactate were chosen as reference (100%). Data represent m
according to Student’s t test.manner similar to the effect induced by the chemical in-
ducer of hypoxia Cobalt(II) Chloride (CoCl2) (Figure 4B).
Importantly, PC3 CM was able to upregulate the hypoxia-
inducible factor 1-alpha (HIF-1α) respect to untreated
cells. The addition of the specific HIF-1α inhibitor, 3-(2-
(4-Adamantan-1-yl-phenoxy)-acetylamino)-4-hydroxyben-
zoic acid methyl ester, counteracted the stimulatory effect
of PC3 CM and CoCl2 on MCT4 expression (Figure 4B).
Interestingly HIF-1α inhibitor determined, after 48 h of
incubation in presence of PC3 CM, a significant reduction
of WI-38 cells respect to control cells cultured without
PC3 CM, suggesting that conditioned fibroblasts devel-
oped a novel addiction for glycolysis (Figure 4C). The
L-lactate enriched medium from conditioned WI-38
cells, but not medium from parental fibroblasts, was
able to significantly sustain the growth of both LNCaP
and PC3 cells in presence of low glucose (Figure 5A).
The mitogenic effect was suppressed when PCa cells
were silenced for the expression of MCT1. Significantly,LNCaP cells were treated with 5 and 10 mM L-lactate for 24 h and
tivated protein kinase- alpha (AMPK), total and active form (Thr172),
s loading control. Values from densitometric analysis are shown on top
tion. B) In the same experimental condition MCT1 and COX1 expression
say in control-silenced (CTR-sil) prostate cells, MCT1-silenced (MCT1-sil)
and in presence or not of 5 mM L-lactate (lac). Cells cultured in 0.6 g/L
ean values ± SD from at least three independent experiments. *P < 0.01
Figure 4 Stimulation of glycolysis in human fibroblasts. Diploid human fibroblasts WI-38 were cultured in presence of 30% PC3-conditioned
medium (CM), or two concentrations of Cobalt(II)Chloride (CoCl2, 100 and 200 μM). A) After 24 h, cell media were collected and the rate of
secreted L-lactate was calculated normalizing for protein content and time of culture. B) The same experimental conditions were repeated
in presence of 50 μM HIF-1α inhibitor (iHIF-1α) and total cell lysates from fibroblasts were analyzed by western blot for the expression of
MCT4 and HIF-1α. Values from densitometric analysis are shown at the bottom of each protein band and were calculated as described in
the Methods section. C) Representative images taken by phase contrast microscopy of WI-38 cells cultured for 48 h in presence of 30% PC3
conditioned medium and 50 μM HIF-1α inhibitor. In insets the mean percentage ± SD of viable WI-38 cells from three different experiments
is shown.
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cell proliferation also in absence of exogenous L-lactate.
The effect of L-lactate was also suppressed by metformin,
a well-known AMPK agonist. Then we sought to verify if
the co-inoculation with conditioned fibroblasts deter-
mined also in vivo an effective proliferative stimulus for
PCa cells. In particular LNCaP cells are only moderately
tumorigenic in nude mice and when inoculated sc in in-
tact nude mice, formed tumor starting from 50 days after
inoculation in about 30% of mice injected with 1*106 cells.
The co-injection of PCa cells with conditioned fibroblasts
(WI38C) in immunodeficient mice determined an impres-
sive acceleration in tumor growth (Figure 5B). Within the
first week after the PCa cells injection the experimental
group containing conditioned fibroblasts was the only
group developing palpable tumors. The presence of paren-
tal fibroblasts was also able to accelerate tumor growth re-
spect to the control group receiving only PCa cells. At
endpoint (35 days) no tumors were detected in the control
group injected with LNCaP cells alone. When MCT1 was
silenced in PCa cells, the stimulatory effect on tumor
growth was almost completely abolished (Figure 5B). A
similar inhibitory effect was also exerted by metformin.
When we analyzed tumor tissues from PC3 xenograftsobtained by co-inoculation with WI38C, we observed that
MCT1 was expressed by tumor cells while MCT4 was
mainly localized in vimentin/α-SMA-positive stromal cells
(Figure 5C).
MCT1 and MCT4 expression in prostate tissue
In order to further support our hypothesis, we investi-
gated the expression of MCTs in PCa (N = 80) and be-
nign hypertrophy (BPH, N = 60) tissues. We considered
age and BMI in order to avoid significant differences
among patients for these parameters. PSA and testoster-
one, but not insulin, resulted significantly higher in PCa
subjects (Table 1).
Prostate specimens from radical prostatectomy (for
PCa subjects) or transurethral resection of prostate (for
BPH subjects) were processed for immunohistochemical
detection of MCT1 and MCT4 (Figure 6). In non tu-
moral tissue, MCT1 was restricted to epithelial cells,
mainly in basal cells and in the basolateral plasma mem-
brane of luminal cells (Figure 6A). On the contrary
MCT4 was not detectable in normal epithelial cells, but
its staining was present as scattered distribution in stro-
mal compartment (Figure 6B). A similar distribution of
MCTs was also observed in BPH tissues, but frequently
Figure 5 (See legend on next page.)
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(See figure on previous page.)
Figure 5 Effect of MCT1 silencing in vitro and in vivo. A) WI-38 conditioned medium recovered from fibroblasts treated with PC3-CM (WI38C
CM) were added to PC3 and LNCaP cells cultured for 48 h in medium containing 0.6 g/L glucose. Proliferation assay was performed measuring
the number of viable cells in control-silenced (CTR-sil) PCa cells, MCT1-silenced (MCT1-sil) PCa cells and using both WI38C CM and control WI-38
conditioned medium (WI38 CM). PCa cells cultured with WI38 CM were also treated with 5mM metformin. In blots time-course MCT1 expression
in control and silenced PCa cells used in the proliferation assays was analyzed. Beta-tubulin detection was utilized as loading control. B) LNCaP
and PC3 cells were injected alone or together with WI-38 cells s.c. in the flank of immunodeficient mice. Tumor growth was monitored daily and
tumor growth was measured by a caliper. Experimental groups included: PCa cells alone; PCa cells injected with WI-38 fibroblasts; PCa cells
injected with PC3-CM conditioned WI-38 fibroblasts (WI38C); MCT1-silenced PCa cells injected with WI38C; PCa cells injected with WI38C and
treated with 50mg/kg metformin. *P>0.01 according to Student’s t test between PC3+WI38C and PC3+WI38 series. C) representative images of
IHC analysis of xenograft tissue from mice inoculated with PC3 and WI38C (magnification 100x).
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neoplastic tissue (Figure 6C and D). In tumor tissue
MCT1 expression remained restricted to carcinoma cells
but its expression pattern was more diffuse involving the
whole plasma membrane (Figure 6E). The increase in
MCT1 expression and its re-localization on plasma
membrane was particularly evident in intraepithelial le-
sions (Figure 6G). In tumor tissue MCT4 staining was
particularly intense in tumoral stroma (Figure 6F). Inter-
estingly we observed a strong positivity for MCT4, but
not for MCT1, in striate muscle localized in peripheral
prostatic gland (Figure 6H).
We assigned a score to MCT1 and MCT4 expression
according to Remmele scoring system (see Methods)
and scores were categorized in low expression (< 6
points) and high expression (≥ 6 points). MCT4 expres-
sion, in both epithelial and stromal compartments, was
significantly upregulated in cancer respect to hyper-
trophic tissue (Table 2). MCT1 expression failed to reach
a statistically significant difference between PCa and
BPH, however when correlation coefficients were calcu-
lated, we individuated a positive correlation between
MCT4 espressed in the stroma and MCT1 expressed in
tumor cells (Table 3).
Discussion
The processes underlying the metabolic adaptation in nor-
mal and pathologic conditions are increasingly studied.Table 1 Selected anthropometric and metabolic variables
in patients with prostate cancer (PCa), and benign
prostatic hyperplasia (BPH) patients
Variable PCa (N = 80) BPH (N = 60) P
Age, y (mean ± SD) 64.0 ± 7.2 65.2 ± 6.5 ns
BMI, kg/m2 (mean ± SD) 27.55 ± 4.36 27.04 ± 4.59 ns
PSA, ng/mL (median ± SE) 7.12 ± 2.16 3.88 ± 0.64 <0.05
Testosterone, ng/mL (median ± SE) 5.83 ± 2.52 3.92 ± 2.12 <0.05
Insulin, mcUI/mL (mean ± SD) 8.8 ± 6.3 7.8 ± 7.6 ns
Gleason 6 (N) 45 -
Gleason 7 (N) 35 -
ns = not statistically significant.The individuation of the metabolic hallmarks that deter-
mine a proliferative advantage in energy restrictive envi-
ronments will represent an important advancement in the
future treatment of aggressive cancers. MCTs may play a
pivotal role in metabolic adaptation because they can
regulate both energetic supply and intracellular pH. We
confirmed that MCT1 and MCT4 were frequently overex-
pressed in prostate tissue, and, importantly, we reported
for the first time the upregulation of MCT4 in the stromal
compartment. In order to understand the clinical impact
of these differences we investigated their functional role
in vitro and in vivo.
We demonstrated that the principal importer of
monocarboxylate acids, MCT1 is present in non tumoral
prostate epithelium, and its expression is evident in basal
cells and in the baso-lateral plasma membrane of
secretory cells. This evidence induced us to hypothesize
that MCT1 can play an important role in feeding normal
prostate epithelium. Takebe et al. described similar MCT1
expression along the basolateral membrane of crypt cells
in mouse intestinal epithelium and of acinar cells in the
mouse mammary glands and they suggested that intensi-
fied expression of MCT1 was associated with renewing
tissues [20,21]. An elevated expression of MCT1 was usu-
ally evident in intraepithelial lesions and it was frequently
associated with an increased MCT4 expression in the
neighbor stromal compartment. Moreover a significant
correlation between tumor MCT1 and stromal MCT4 ex-
pression exists. Also in BPH tissues, MCT4 was frequently
upregulated in stromal cells while cells within hyper-
trophic glands showed a more diffuse pattern in MCT1
expression. This characteristic did not permit to individu-
ate a significant association between MCT1 expression
and tumor tissue respect to BPH tissue. Accordingly,
other authors have individuated MCT1 expression in
prostate epithelium and in PIN lesions, and they did not
find any correlation with cancer progression [22,23]. A
similar condition was observed also in PC3 and LNCaP
xenografts where tumor masses contain a complex net of
associated fibroblasts as evidenced by staining for vimen-
tin and αSMA. In our in vivo model MCT4 was mainly
expressed just by these associated fibroblasts, suggesting
their early metabolic conditioning by tumor cells.
Figure 6 Representative images of immunohistochemical detection for MCT1 and MCT4 in prostate tissue. MCT1: A) non-neoplastic epithelium;
C) benign hyperplasia; E) tumor; G) intraepithelial neoplastic lesion. MCT4: B) non-neoplastic epithelium; D) benign hyperplasia, F) tumor. H) MCT1 and
MCT4 expression in striate muscle in the periphery of prostate gland. Images taken at 100x magnification. Inset shows a 3x magnification of the image.
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Table 2 Pathological conditions associated with MCT1
and MCT4 expression
Tissue
Expression/total number (%) P-
value#Null Low* High**
MCT1
BPH 48% (29/60) 47% (28/60) 5% (3/60)
0.07
PCa 31% (25/80) 56% (45/80) 13% (10/80)
MCT4
BPH 92% (55/60) 5% (3/60) 3% (2/60)
<0.01
PCa 35% (28/80) 45% (36/80) 20% (16/80)
Stromal MCT4
BPH 50% (30/60) 45% (27/60) 2% (3/60)
<0.01
PCa 25% (20780) 61% (49/80) 14% (11/80)
*Low (grade <6 immunostaining); ** high (grade ≥6 immunostaining); # χ2 test.
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based upon lactic acid shuttle between stromal and epi-
thelial cells. In fact, in non-neoplastic prostate tissue,
MCT4, the principal exporter of L-lactate, was seen only
in stromal compartment and in striate muscle. It is pos-
sible that in particular pathophysiologic conditions pros-
tate stromal cells can fuel epithelial cells. To describe
this phenomenon, some authors have coined the denom-
ination of “reverse Warburg effect” [13]. Similar ener-
getic symbiosis is present in other organs, such as brain
and ovary, also in absence of a rapid energetic expend-
iture, or hypoxic pressure [24,25]. It can be hypothesized
that these metabolic associations have a protective role
for those cells that are highly dependent on a quickly
available energy supply, like in the case of neurons or
oocytes.
An emerging hypothesis is that cancer-associated fi-
broblasts are forced to undergo aerobic glycolysis
through cancer-induced mitophagy. Many are the pos-
sible causes of this phenomenon: systemic factors, such
as circulating hormone, cytokines or growth factors;
local factors produced by tumor cells or infiltrating in-
flammatory cells; local hypoxia. For example, prostate
tumors have been shown to be significantly oxygen-
deprived. Hypoxia has been reported to up-regulate
MCT4, but not MCT1, in rat skeletal muscle [26], and in
some tumor cells [27], at least in part through a transcrip-
tional mechanism. The evidence that pO2 measurementsTable 3 Pearson’s correlation coefficients calculated for
epithelial MCT1, MCT4 and stromal MCT4 expression in
cancer tissue
MCT1 MCT4 Stromal MCT4
MCT1 1 −0.118 (0.715)* 0.645 (0.024)
MCT4 −0.118 (0.715) 1 −0.304 (0.337)
Stromal MCT4 0.645 (0.024) −0.304 (0.337) 1
*P-value.resulted very heterogeneous in tumors with similar Glea-
son score is in agreement with our data indicating a vari-
able expression of MCT4 [17]. Our results suggest that
the “reverse Warburg effect” could be induced by direct
interaction between cancer cells and fibroblasts. In fact,
the soluble factors released by PC3 cells are sufficient to
increase the release of L-lactate by human fibroblasts. The
mentioned soluble factors released by PCa cells not only
did induce HIF-1α, and MCT4 expression but did also
stimulate in fibroblasts a HIF-1α-dependent phenotype.
Indeed tumor presence may induce a stressful condition
in adjacent normal cells with an increased release of ca-
tabolized nutrients, such as ketone bodies, glutamine and
L-lactate [28]. As recently demonstrated this metabolic-
coupling mechanism could be utilized also by prostate
cancer cells promoting carcinogenesis or sustaining cancer
progression, and it is based upon the release of reactive
oxygen species by tumor cells [29]. Similarly, breast
cancer cells can trigger aerobic glycolysis and oxidative
stress in neighboring fibroblasts by secreting hydrogen
peroxide [30].
Our results, in agreement with available data, support
the hypothesis of a major role of MCTs in the emer-
gence of a highly glycolytic phenotype, representing an
adaptation to the hypoxic, or rapidly changing micro-
environment. The up-regulation of MCT4 and the main-
tenance of MCT1 in the plasma membrane of PCa cells
appears to be the principal adaptive mechanism to allow
continuous and high glycolytic rates, by exporting the
accumulating end-product, L-lactate, as well as to coun-
teract acid-induced death [31]. PCa cells lines express
both L-lactate transporters and their expression could be
modulated by tumor cells according to environmental
needs. This characteristic is present also in transformed
prostate epithelial cells RWPE-1 and WPE1-NB26, sug-
gesting an early energetic adaptability along tumorigen-
esis. However we have to consider the limitations of the
available cell models. We observed that although WPE1
cells expressed higher levels of MCT4 and L-lactate ex-
port rate respect to RWPE-1 cells, these latter had a L-
lactate production comparable with that of PC3 cells.
Because increased glycolysis and adaptation to acidosis
are key events in the transition from in situ to invasive
cancer, these data are surprising. It is possible that the
modality of cell transformation plays a pivotal role in de-
termining the cellular metabolism. Accordingly, it has
been demonstrated in several tumorigenic and non-
tumorigenic HPV-18 infected cell lines that an appropri-
ate level of glycolysis is an essential prerequisite for the
maintenance of HPV gene expression [32].
Conclusions
We identified MCT1 as a potential target in PCa ther-
apy. In fact the inhibition of MCT1 transport was able
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in vivo. However this therapeutic opportunity was evi-
dent only in specific conditions. Our data indicate that
the inhibition of MCT1 is particularly dramatic for en-
ergy metabolism in presence of low glucose concentra-
tions. Interestingly at glucose concentrations normally
used in the cancer cell culture medium the addition of
L-lactate resulted in the inhibition of prostate cell prolif-
eration. It is possible that the overload of lactate in high-
proliferating cells in conjuction with acidification of
medium was sufficient to create sub-optimal growth
conditions already after 48 h of treatment. Indeed the
pro-survival and mitogenic effects of L-lactate were
mainly important in low density cell culture and in sus-
taining the initial growth of xenografts. In these condi-
tions, hypoxia and acidification probably play a limited
role in conditioning directly tumor cell phenotype. In
previous studies, targeting MCT1 has shown anticancer
effects in tumor xenograft models and this phenomenon
was associated with the L-lactate shuttle [14]. However
other in vivo studies have failed to confirm similar re-
sults [31]. Contradictory data may be the result of the
different tumor models used and of the complexity in
metabolic adaptation of cancer cells. The evidence for a
dual effect of L-lactate according to glucose availability
needs further investigation in order to individuate the
molecular sensors able to modulate intracellular energy
pathways in response to environmental changes. We ob-
served that L-lactate was able to reduce the activation of
the master sensor of energy status AMPK, and this
phenomenon is compatible with sustained anabolic me-
tabolism, allowing cancer cells to escape its restraining
influence on survival and growth. The inhibitory effect
by metformin, observed both in vitro and in vivo, con-
firmed that an AMP agonist could play an important
role in glucose-deprived environment compromising the
metabolic adaptation by cancer cells.
Because significant differences in the expression and
localization of MCTs have been detected in cancer cases
with similar grading and staging, the future validation of
these data could have a favorable impact on diagnosis
and treatment of the more aggressive prostate cancers.
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